An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
about
Targeted drugs in small-cell lung cancerScientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in CancerAurora kinase A in gastrointestinal cancers: time to targetPhase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.Small cell lung cancer: where do we go from here?Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.Small cell lung cancer: will recent progress lead to improved outcomes?Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein ProfilingTargeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.A framework for identification of actionable cancer genome dependencies in small cell lung cancer.Targeting MYC in cancer therapy: RNA processing offers new opportunities.Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.Personalized chemotherapy selection for breast cancer using gene expression profilesAurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.Myc-induced glutaminolysis bypasses HIF-driven glycolysis in hypoxic small cell lung carcinoma cells.Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies.MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.Family matters: How MYC family oncogenes impact small cell lung cancer.Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.Treponema denticola increases MMP-2 expression and activation in the periodontium via reversible DNA and histone modifications.A Rapid and Sensitive Next-Generation Sequencing Method to Detect RB1 Mutations Improves Care for Retinoblastoma Patients and Their Families.A double-negative feedback loop between EpCAM and ERK contributes to the regulation of epithelial-mesenchymal transition in cancer.Molecular alterations of neuroendocrine tumours of the lung.Biology and evolution of poorly differentiated neuroendocrine tumors.An exploration of pathways involved in lung carcinoid progression using gene expression profiling.Retinoblastoma
P2860
Q26767017-DECA349D-4AB5-4007-BD76-68136F218B51Q26784060-44064F9F-7986-4D15-AC67-2211BCA9773AQ26864277-648EC6A4-51EF-489E-9408-810F7DD68ABAQ33412196-72AE455E-EFD3-4847-99A0-30717840D2C7Q33872327-410AB932-69B9-4341-9758-119D1A034E41Q34498390-A4750A21-7AD4-47D4-94ED-E9F483EBD411Q35605425-09CEA510-8949-44CA-90DB-C4FD557CEFF5Q35836257-21A62317-8F94-4E1C-96CD-B371808B2C17Q35895426-C1BAB75C-49C8-4C05-8645-B53FB54A0DA0Q36164893-5C66568F-0038-43E4-AB68-77A1643EE162Q36342432-22702FE8-1B0F-4CCB-A973-BF79A890F391Q36762189-C2DD50A8-D37C-4EB3-8BB4-DF6E51DBB899Q37580388-9B2C3854-D43B-491E-B74A-4B4081B44663Q37679039-E5F93EF8-8350-451C-8EC9-81C4D9AB002FQ38223271-00A035E5-C519-4B26-8BB2-DC6062C9723DQ38753586-D95AF2F5-1D42-426F-84F5-05DD609A156DQ38826776-514C88A1-DD32-4275-B992-08538355A1F1Q38894287-DCBBC79C-3C14-4CDF-91ED-06FCB42C6AA0Q39001858-FB07B0A7-33F0-4BBD-9691-6ABBFA0006EBQ39019412-722EBB6A-A5F2-4EC1-A166-96A994EC26E0Q39454070-B407EC46-940F-465D-9BE9-F38CB3E34F67Q40440921-9C8C44F2-E9F1-4F1A-8989-D26ECA89F28AQ46021184-45215A75-DCB1-4CBC-A0D2-52DFB0D0B378Q46468588-D3011580-C4B4-48A0-8F60-5E58DE8F2CB8Q47099062-EDC35ED4-FDBE-4FAE-84B7-75A5FD8BBCC3Q47312955-20877539-BD00-4115-A593-7F70EADD397FQ48320507-B01BB89E-A45D-4E39-9B00-60A8E42A62EFQ50728982-8FADB38E-4FEE-4E5D-B2FE-86C716A98779Q58347703-D55AC1AD-A56D-4020-867C-931A207DBD6A
P2860
An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
An integrated genomic approach ...... kinase inhibitor PF-03814735.
@en
An integrated genomic approach ...... kinase inhibitor PF-03814735.
@nl
type
label
An integrated genomic approach ...... kinase inhibitor PF-03814735.
@en
An integrated genomic approach ...... kinase inhibitor PF-03814735.
@nl
prefLabel
An integrated genomic approach ...... kinase inhibitor PF-03814735.
@en
An integrated genomic approach ...... kinase inhibitor PF-03814735.
@nl
P2093
P1476
An integrated genomic approach ...... kinase inhibitor PF-03814735.
@en
P2093
Adam Pavlicek
James G Christensen
Jingjing Ye
Julie L C Kan
Keith A Ching
Kenneth E Hook
Mark Ozeck
Maruja E Lira
P304
P356
10.1158/1535-7163.MCT-11-0184
P577
2012-01-05T00:00:00Z